Algert Global LLC Macrogenics Inc Transaction History

Algert Global LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.25 - $9.99 $55,813 - $247,811	-24,806 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $201,424 - $419,221	24,806 New	24,806 $219,000
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $150,586 - $211,595	-12,105 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $126,048 - $171,220	-8,687 Reduced 41.78%	12,105 $205,000
Q1 2019 May 01, 2019	SELL	$11.11 - $25.6 $206,068 - $474,828	-18,548 Reduced 47.15%	20,792 $374,000
Q4 2018 Feb 01, 2019	BUY	$11.75 - $21.42 $346,989 - $632,554	29,531 Added 301.06%	39,340 $500,000
Q2 2018 Aug 02, 2018	BUY	$19.78 - $24.67 $194,022 - $241,988	9,809 New	9,809 $203,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.